These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 20610171

  • 41. Activation of TRPA1 channels by the fatty acid amide hydrolase inhibitor 3'-carbamoylbiphenyl-3-yl cyclohexylcarbamate (URB597).
    Niforatos W, Zhang XF, Lake MR, Walter KA, Neelands T, Holzman TF, Scott VE, Faltynek CR, Moreland RB, Chen J.
    Mol Pharmacol; 2007 May; 71(5):1209-16. PubMed ID: 17314320
    [Abstract] [Full Text] [Related]

  • 42. Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets.
    Zhang D, Saraf A, Kolasa T, Bhatia P, Zheng GZ, Patel M, Lannoye GS, Richardson P, Stewart A, Rogers JC, Brioni JD, Surowy CS.
    Neuropharmacology; 2007 Mar; 52(4):1095-105. PubMed ID: 17217969
    [Abstract] [Full Text] [Related]

  • 43. Enol carbamates as inhibitors of fatty acid amide hydrolase (FAAH) endowed with high selectivity for FAAH over the other targets of the endocannabinoid system.
    Gattinoni S, De Simone C, Dallavalle S, Fezza F, Nannei R, Amadio D, Minetti P, Quattrociocchi G, Caprioli A, Borsini F, Cabri W, Penco S, Merlini L, Maccarrone M.
    ChemMedChem; 2010 Mar 01; 5(3):357-60. PubMed ID: 20112328
    [No Abstract] [Full Text] [Related]

  • 44. Effects of URB597 as an inhibitor of fatty acid amide hydrolase on modulation of nociception in a rat model of cholestasis.
    Hasanein P, Shahidi S, Komaki A, Mirazi N.
    Eur J Pharmacol; 2008 Sep 04; 591(1-3):132-5. PubMed ID: 18593578
    [Abstract] [Full Text] [Related]

  • 45. Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate.
    Vandevoorde S, Fowler CJ.
    Br J Pharmacol; 2005 Aug 04; 145(7):885-93. PubMed ID: 15895107
    [Abstract] [Full Text] [Related]

  • 46. The fatty acid amide hydrolase C385A variant affects brain binding of the positron emission tomography tracer [11C]CURB.
    Boileau I, Tyndale RF, Williams B, Mansouri E, Westwood DJ, Le Foll B, Rusjan PM, Mizrahi R, De Luca V, Zhou Q, Wilson AA, Houle S, Kish SJ, Tong J.
    J Cereb Blood Flow Metab; 2015 Aug 04; 35(8):1237-40. PubMed ID: 26036940
    [Abstract] [Full Text] [Related]

  • 47. Inhibition of fatty acid amide hydrolase (FAAH) reduces spinal nociceptive responses and expression of spinal long-term potentiation (LTP).
    Eriksen GS, Jacobsen LM, Mahmood A, Pedersen LM, Gjerstad J.
    Brain Res Bull; 2012 Feb 10; 87(2-3):234-7. PubMed ID: 22133920
    [Abstract] [Full Text] [Related]

  • 48. Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes.
    Alexander JP, Cravatt BF.
    Chem Biol; 2005 Nov 10; 12(11):1179-87. PubMed ID: 16298297
    [Abstract] [Full Text] [Related]

  • 49. Synthesis and Preclinical Evaluation of Sulfonamido-based [(11)C-Carbonyl]-Carbamates and Ureas for Imaging Monoacylglycerol Lipase.
    Wang L, Mori W, Cheng R, Yui J, Hatori A, Ma L, Zhang Y, Rotstein BH, Fujinaga M, Shimoda Y, Yamasaki T, Xie L, Nagai Y, Minamimoto T, Higuchi M, Vasdev N, Zhang MR, Liang SH.
    Theranostics; 2016 Nov 10; 6(8):1145-59. PubMed ID: 27279908
    [Abstract] [Full Text] [Related]

  • 50. Quantum mechanics/molecular mechanics modeling of fatty acid amide hydrolase reactivation distinguishes substrate from irreversible covalent inhibitors.
    Lodola A, Capoferri L, Rivara S, Tarzia G, Piomelli D, Mulholland A, Mor M.
    J Med Chem; 2013 Mar 28; 56(6):2500-12. PubMed ID: 23425199
    [Abstract] [Full Text] [Related]

  • 51. Biochemical characterization and in vitro activity of AZ513, a noncovalent, reversible, and noncompetitive inhibitor of fatty acid amide hydrolase.
    Scott CW, Tian G, Yu XH, Paschetto KA, Wilkins DE, Meury L, Cao CQ, Varnes J, Edwards PD.
    Eur J Pharmacol; 2011 Sep 30; 667(1-3):74-9. PubMed ID: 21645511
    [Abstract] [Full Text] [Related]

  • 52. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
    Gaetani S, Dipasquale P, Romano A, Righetti L, Cassano T, Piomelli D, Cuomo V.
    Int Rev Neurobiol; 2009 Sep 30; 85():57-72. PubMed ID: 19607961
    [Abstract] [Full Text] [Related]

  • 53. FAAH inhibition attenuates TLR3-mediated hyperthermia, nociceptive- and anxiety-like behaviour in female rats.
    Flannery LE, Kerr DM, Finn DP, Roche M.
    Behav Brain Res; 2018 Nov 01; 353():11-20. PubMed ID: 29953903
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.
    Gattinoni S, Simone CD, Dallavalle S, Fezza F, Nannei R, Battista N, Minetti P, Quattrociocchi G, Caprioli A, Borsini F, Cabri W, Penco S, Merlini L, Maccarrone M.
    Bioorg Med Chem Lett; 2010 Aug 01; 20(15):4406-11. PubMed ID: 20591666
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Reducing endocannabinoid metabolism with the fatty acid amide hydrolase inhibitor, URB597, fails to modify reinstatement of morphine-induced conditioned floor preference and naloxone-precipitated morphine withdrawal-induced conditioned floor avoidance.
    McCallum AL, Limebeer CL, Parker LA.
    Pharmacol Biochem Behav; 2010 Oct 01; 96(4):496-500. PubMed ID: 20643159
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Radiosynthesis, in vitro and in vivo evaluation of 123I-labeled anandamide analogues for mapping brain FAAH.
    Wyffels L, De Bruyne S, Blanckaert P, Lambert DM, De Vos F.
    Bioorg Med Chem; 2009 Jan 01; 17(1):49-56. PubMed ID: 19054678
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.